Galimedix Therapeutics presents sturdy pharmacokinetic profile of next-generation oral Alzheimer’s candidate at AD/PD™ 2026

Mineralys Therapeutics Studies Inducement Awards Below Nasdaq Itemizing Rule 5635(c)(4)